Treatment Adherence of Anti-TNF Drugs in the Patients with Inflammatory Bowel Disease: A Scale Development Study

被引:0
|
作者
Basak, Nur [1 ]
Uran, Berna Nilgun Ozgursoy [2 ]
Yuksel, Elif Saritas [3 ]
机构
[1] Izmir Katip Celebi Univ, Inst Hlth Sci, Internal Med Nursing Dept, Izmir, Turkey
[2] Izmir Katip Celebi Univ, Fac Hlth Sci, Izmir, Turkey
[3] Izmir Katip Celebi Univ, Med Sch, Izmir, Turkey
来源
TURKISH JOURNAL OF GASTROENTEROLOGY | 2022年 / 33卷 / 04期
关键词
Anti-TNF alpha; IBD; reliability; scale development; treatment compliance; validity; MEDICATION ADHERENCE; THERAPY; NONADHERENCE; RISK;
D O I
10.5152/tjg.2022.211170
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: This work studies the validity and reliability of the Anti-TNF Alpha Treatment Adherence Scale, which has newly been developed to measure the compliance of inflammatory bowel disease patients using the anti-TNF alpha agents that are widely used in gastroenterology and rheumatology clinics. Methods: The study group consisted of 165 irritable bowel disease patients aged 18 years and above who were using anti-TNF alpha drugs. After creating a question pool with 40 items, the pilot study was applied with 70 patients. SPSS 25.0 and AMOS programs were used. item-total correlation coefficients, Cronbach's alpha and test-retest analysis, missing data, extreme value, normality, 27% sub-upper item discrimination analysis, and exploratory and confirmatory factor analyses were used. Results: The factor structure of the scale was examined with exploratory and confirmatory factor analyses and the contribution of these components to the total variance was measured as 74.21%. The Anti-TNF Alpha Treatment Adherence Scale was found in relation to the scale structure consisting of 12 items and 4 sub-dimensions. According to the first level multifactorial analysis results, the goodness of fit identities of the scale were found at an acceptable level, with the following values: RMSEA 0.067; GFI 0.92; AGFI 0.87; CFI 0.95; and chi(2) 79.876 (P = .000). Conclusion: It was determined that the Anti-TNF Alpha Treatment Adherence Scale represents the area to be measured, measures the researched structure, has a high internal consistency between items, is interrelated, and is consistent over time. As a result of all measurements, it was determined that it is a valid and reliable scale.
引用
收藏
页码:336 / +
页数:12
相关论文
共 50 条
  • [21] Cytomegalovirus, inflammatory bowel disease, and anti-TNFα
    Sara T. Campos
    Francisco A. Portela
    Luís Tomé
    International Journal of Colorectal Disease, 2017, 32 : 645 - 650
  • [22] Characterization of Disease Course and Treatment in Patients With Inflammatory Bowel Disease and Anti-TNF Induced Psoriasis
    Liu, Mona
    Grandinetti, Lisa
    Barrie, Arthur
    Saul, Melissa
    Regueiro, Miguel
    Swoger, Jason
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S505 - S505
  • [23] Progression to Anti-TNF Treatment in Very Early Onset Inflammatory Bowel Disease Patients
    Eindor-Abarbanel, Adi
    Meleady, Laura
    Lawrence, Sally
    Hamilton, Zachary
    Krikler, Gena
    Lakhani, Alam
    Zhang, Qian
    Jacobson, Kevan
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2022, 75 (04): : 473 - 479
  • [24] ACTIVE TUBERCULOSIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER TREATMENT WITH ANTI-TNF THERAPY
    Owen, L.
    Thi, A. A.
    Bouri, S.
    Wolfson, P.
    Abbara, A.
    John, L.
    Davidson, R. N.
    Hart, A. L.
    GUT, 2016, 65 : A252 - A253
  • [25] Demyelinating Disease Complicating the Use of Anti-TNFα in the Treatment of Inflammatory Bowel Disease: A Retrospective Study
    Ebuh, Valentine
    Singh, Anupam
    Ionete, Carolina
    Zawacki, John
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S471 - S472
  • [26] Longitudinal Outcomes of Anti-TNF Therapy in the Treatment of Inflammatory Bowel Disease
    Roney, Andrew R.
    Orr, Dupre
    Barghi, Armeen
    Cusumano, Vivy
    Limketkai, Berkeley
    Sauk, Jenny
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S768 - S769
  • [27] Dermatological Lesions in Patients With Inflammatory Bowel Diseases on Use of Anti-TNF Drugs
    Steinwurz, Flavio
    Carvalho, Nayara S.
    Miranda, Maria Luiza Q.
    Flaquer, Fernando S.
    Vieira, Andrea
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S1675 - S1675
  • [28] ANTI-TNF WITHDRAWAL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN ENDOSCOPIC REMISSION: A PROSPECTIVE STUDY
    Mahmoud, Remi
    Savelkoul, Edo
    Mares, Wout
    Goetgebuer, Rogier
    Witteman, Ben
    de Koning, Daan
    Minderhoud, Itta M.
    van Tuyl, Sebastiaan
    van Boeckel, Petra G.
    Mahmmod, Nofel
    Lutgens, Maurice
    Horje, Carmen S. Horjus Talabur
    Romkens, Tessa E. H.
    Akol-Simsek, Dilek
    Jansen, Jeroen M.
    Colombel, Jean Frederic
    Hoentjen, Frank
    Jharap, Bindia
    Oldenburg, Bas
    GASTROENTEROLOGY, 2022, 162 (07) : S809 - S809
  • [29] Familial Aggregation in the Response to Anti-TNF in Inflammatory Bowel Disease Patients
    Billiet, Thomas
    Cleynen, Isabelle
    Ballet, Vera
    Ferrante, Marc
    Van Steen, Kristel
    Rutgeerts, Paul J.
    Vermeire, Severine
    GASTROENTEROLOGY, 2013, 144 (05) : S647 - S647
  • [30] Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy
    Miranda-Bautista, Jose
    de Gracia-Fernandez, Celia
    Lopez-Ibanez, Maria
    Barrientos, Maria
    Gallo-Molto, Alejandra
    Gonzalez-Arias, Marina
    Gonzalez-Gil, Casilda
    Diaz-Redondo, Alicia
    Marin-Jimenez, Ignacio
    Menchen, Luis
    DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (07) : 2130 - 2135